Resection of Recurrent Pancreatic Cancer: Who Can Benefit?
| Autor: | Martin F. Schneider, Markus W. Büchler, Henrik Nienhüser |
|---|---|
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Visc Med |
| ISSN: | 2297-475X 2297-4725 |
| DOI: | 10.1159/000519754 |
| Popis: | Background: Recurrence after resection of pancreatic cancer occurs in up to 80% of patients in the first 2 years after complete resection. While most patients are not eligible for surgical treatment due to disseminated disease, a certain group of patients can be evaluated for re-resection of local recurrence. This review summarizes the current literature on surgical treatment of recurrent pancreatic cancer and potential prognostic factors. Summary: Re-resection of recurrent pancreatic cancer provides a significant survival benefit to selected patients with acceptable procedure-related mortality. Median overall survival after re-resection of recurrent pancreatic cancer is up to 28 months. The most relevant clinical parameters associated with a prognostic benefit are young patient age (10 months), and preoperative chemotherapy before re-resection. Molecular markers are currently under investigation and might help to improve patient selection in the future. Key Message: Re-resection of recurrent pancreatic cancer is safe and feasible in experienced hands. Selected patients benefit from surgical treatment, but future studies are needed to identify reliable prognostic markers predicting survival. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|